Literature DB >> 20818675

Bone metastases: molecular mechanisms and novel therapeutic interventions.

Dionysios J Papachristou1, Efthimia K Basdra, Athanasios G Papavassiliou.   

Abstract

It has been long recognized that skeleton represents one of the most favored metastatic sites for common cancers like breast and prostate. During the last decade the molecular mechanisms that are responsible for the development of bone metastasis have been gradually illuminated. It appears that the bone microenvironment has a pivotal role in this process. Metastatic tumor cells interact with bone triggering a cascade of molecular events that produce osteolytic and/or osteoblastic phenomena. In this review, we summarize and discuss the most significant factors and signaling pathways implicated in bone colonization. Moreover, based on the recent literature and data, we foresee the need for designing novel agents that will efficiently disrupt these interactions among cancer cells and bone microenvironment, bringing hope for more effective treatments.
© 2010 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20818675     DOI: 10.1002/med.20224

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


  25 in total

1.  Digital metastasis presenting as infection.

Authors:  Vasileios Kontogeorgakos; Anastasios Korompilias; Miltiadis Georgousis; Dionysios Papachristou
Journal:  J Hand Microsurg       Date:  2010-12-31

Review 2.  Bone Pain and Muscle Weakness in Cancer Patients.

Authors:  Daniel P Milgrom; Neha L Lad; Leonidas G Koniaris; Teresa A Zimmers
Journal:  Curr Osteoporos Rep       Date:  2017-04       Impact factor: 5.096

3.  Cathepsin B inhibition limits bone metastasis in breast cancer.

Authors:  Nimali P Withana; Galia Blum; Mansoureh Sameni; Clare Slaney; Arulselvi Anbalagan; Mary B Olive; Bradley N Bidwell; Laura Edgington; Ling Wang; Kamiar Moin; Bonnie F Sloane; Robin L Anderson; Matthew S Bogyo; Belinda S Parker
Journal:  Cancer Res       Date:  2012-01-19       Impact factor: 12.701

Review 4.  Myeloid-derived suppressor cells as osteoclast progenitors: a novel target for controlling osteolytic bone metastasis.

Authors:  Anandi Sawant; Selvarangan Ponnazhagan
Journal:  Cancer Res       Date:  2013-07-25       Impact factor: 12.701

Review 5.  Bone-targeted therapies for elderly patients with renal cell carcinoma: current and future directions.

Authors:  Thomas Roza; Lukman Hakim; Hendrik van Poppel; Steven Joniau
Journal:  Drugs Aging       Date:  2013-11       Impact factor: 3.923

6.  Molecular signature of epithelial-mesenchymal transition (EMT) in human prostate cancer bone metastasis.

Authors:  Seema Sethi; Jill Macoska; Wei Chen; Fazlul H Sarkar
Journal:  Am J Transl Res       Date:  2010-10-23       Impact factor: 4.060

Review 7.  Deciphering signaling networks in osteosarcoma pathobiology.

Authors:  Christos Adamopoulos; Antonios N Gargalionis; Efthimia K Basdra; Athanasios G Papavassiliou
Journal:  Exp Biol Med (Maywood)       Date:  2016-05-06

8.  METTL3 enhances cell adhesion through stabilizing integrin β1 mRNA via an m6A-HuR-dependent mechanism in prostatic carcinoma.

Authors:  Ermao Li; Bo Wei; Xiaolan Wang; Ran Kang
Journal:  Am J Cancer Res       Date:  2020-03-01       Impact factor: 6.166

Review 9.  Slit/Robo pathway: a promising therapeutic target for cancer.

Authors:  Rishi K Gara; Sonam Kumari; Aditya Ganju; Murali M Yallapu; Meena Jaggi; Subhash C Chauhan
Journal:  Drug Discov Today       Date:  2014-09-20       Impact factor: 7.851

10.  Induction of thermal and mechanical hypersensitivity by parathyroid hormone-related peptide through upregulation of TRPV1 function and trafficking.

Authors:  Aaron D Mickle; Andrew J Shepherd; Lipin Loo; Durga P Mohapatra
Journal:  Pain       Date:  2015-09       Impact factor: 7.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.